ArticleBiomedicines2022

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial.

Akira Sezai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.